FrancophonIA/ELRC3.0 huggingface dataset:
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reactions) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: kura waħda) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal, inklużi rapporti iżolati).
English: 25 ml polyethylene terephthalate (PET) vials 50 ml PET vials
Maltese: Kunjett tal-polyethylene terephthalate (PET) ta' 25 ml Kunjett PET ta' 50 ml
English: 1 HU - haemagglutinating units.
Maltese: 1 HU - unitajiet li jemagglutinaw
English: Maternally-derived antibodies in piglets interfere with the RESPIPORC FLUpan H1N1 mediated immunity.
Maltese: Antikorpi derivati maternalment fi qżieqeż jinterferixxu mal-immunità medjata minn RESPIPORC FLUpan H1N1.
English: Aluminium flanged caps
Maltese: Kapep bi flanġ tal-aluminju
English: Bromobutyl rubber stoppers
Maltese: Tappijiet tal-gomma bromobutyl
English: 0.1 mg For the full list of excipients, see section 6.1.
Maltese: 0.1 mg Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
English: Generally, maternally-derived antibodies induced by vaccination last for approximately 5-8 weeks after birth.
Maltese: Ġeneralment, antikorpi derivati maternalment indotti minn tilqim idumu bejn wieħed u ieħor 5-8 ġimgħat wara t-twelid.
English: Vaccination: 2 injections of one dose (1 ml) from the age of 56 days, with an interval of 3 weeks between injections.
Maltese: Tilqim: 2 injezzjonijiet ta' doża waħda (1 ml) mill-età ta' 56 ġurnata, b'intervall ta' tliet ġimgħat bejn l-injezzjonijiet.
English: RESPIPORC FLUpan H1N1 suspension for injection for pigs
Maltese: VETERINARJU RESPIPORC FLUpan H1N1 suspensjoni għall-injezzjoni għall-majjali
English: Inactivated influenza A virus/human, strain A/Jena/VI5258/2009(H1N1)pdm09: ≥ 16 HU
Maltese: Vajrus tal-Influwenza A/uman inattivat, razza A/Jena/VI5258/2009(H1N1)pdm09: ≥ 16 HU
English: The vaccine stimulates an active immunity against pandemic porcine influenza A/Jena/VI5258/2009 (H1N1)pandemic09-like virus.
Maltese: It-tilqima tistimula immunità attiva kontra virus simili għal A/Jena/VI5258/2009 (H1N1)pandemika09 tal-influwenza pandemika tal-majjali.
English: The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Maltese: L-addittivi (inkluż l-aġġuvanti) elenkati f'sezzjoni 6.1 tal-Karatteristiċi tal-Prodott fil Qosor huma jew sustanzi ammissibbli li għalihom m'hemmx bżonn ta' limiti massimi ta' residwi kif indikat fit tabella numru 1 tal-anness tar-Regolament tal-Kummissjoni (UE) Nru 37/2010 jew huma kkunsidrati li ma jaqgħux fi ħdan l-iskop tar-Regolament (KE) Nru 470/2009 meta użati bħal f'dan il-prodott mediċinali veterinarju.
English: It induces neutralising and haemagglutination-inhibiting antibodies against this subtype.
Maltese: Hija tikkawża antikorpi newtralizzanti u li jinibixxu emagglutinazzjoni kontra dan is-subtip.
English: Name and address of the manufacturer of the biological active substance
Maltese: Isem u indirizz tal-manufattur tas-sustanza bijoloġika attiva IDT Biologika GmbH
English: Pharmacotherapeutic group: Immunologicals, inactivated viral vaccines for pigs, porcine influenza virus.
Maltese: Immunoloġiċi, tilqim virali inattivat għal majjali, vajrus ta' influwenza porċina.
English: Inactivated influenza A virus/human Strain: A/Jena/VI5258/2009(H1N1)pdm09
Maltese: Vajrus tal-Influwenza A/uman inattivat Razza: A/Jena/VI5258/2009(H1N1)pdm09
English: The antibody responses mentioned in the following have been documented in pigs without maternally-derived immunity.
Maltese: Ir-risponsi tal-antikorp imsemmija f'li ġej ġew iddokumentati f'majjali mingħajr immunità derivata maternalment.
English: 7 days after primary vaccination.
Maltese: 7 ijiem wara t-tilqima primarja.
English: Neutralising antibodies in serum have been detected in more than 75% of the immunised pigs on day 7 after primary immunisation, lasting in more than 75% of the pigs for over 3 months.
Maltese: Antikorpi newtralizzanti fis-serum instabu f'aktar minn 75% tal-majjali mlaqqma fis-7 ġurnata wara immunizzazzjoni primarja, li f'aktar minn 75% talmajjali, damu għal aktar minn 3 xhur.
English: Excipient:
Maltese: Tilqim:
English: Haemagglutination-inhibiting antibodies have been detected in 15100% of the immunised pigs on day 7 after primary immunisation which disappeared in the majority of animals within 1 to 4 weeks thereafter.
Maltese: Antikorpi li jinibixxu emagglutinazzjoni nstabu fi 15-100% tal-majjali mlaqqma fis-7 ġurnata wara l-immunizzazzjoni primarja, li sparixxew fil-maġġoranza tal annimali fi żmien ġimgħa sa 4 ġimgħat wara.
English: Disposal: read package leaflet.
Maltese: tagħrif jew it-tikketta lit tabib.
English: Cardboard box with 1 polyethylene terephthalate (PET) vial of 25 doses (25 ml) or 50 doses (50 ml) with a rubber stopper and flanged cap.
Maltese: Kaxxa tal-kartun bi kunjett 1 ta' 25 doża (25 ml) jew 50 doża (50 ml) b'tapp tal-gomma u b'kappa bi flanġ.
English: Caps:
Maltese: Kapep:
English: A transient increase in rectal temperature, not exceeding 2 °C, is common after vaccination and this does not persist for more than one day.
Maltese: Żieda temporanja fit-temperatura rettali, li ma taqbiżx 2 °C, hija komuni wara t-tilqima u din ma ddumx għal aktar minn ġurnata.
English: Active immunisation of pigs from the age of 8 weeks onwards against pandemic H1N1 porcine influenza virus to reduce viral lung load and viral excretion.
Maltese: Immunizzazzjoni attiva ta' majjali mill-età ta' 8 ġimgħat 'il quddiem kontra vajrus ta' influwenza porċina pandemika H1N1 biex titnaqqas it-tagħbija ta' pulmun virali u eskrezzjoni tal-vajrus.
English: Duration of immunity: 3 months after primary vaccination.
Maltese: Perjodu tal-immunità: 3 xhur wara t-tilqima primarja.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box for 25 ml, 50 ml
Maltese: Kaxxa tal-kartun għal 25 ml, 50 ml ISEM
English: In cases of exposure of the sows to antigens (from either field infections and/or vaccination) the antibodies transmitted to the piglets can interfere with active immunisation at 12 weeks of age.
Maltese: F'każijiet ta' esponiment tal majjaliet għall-antiġeni (minn infezzjonijiet tar-raba' u/jew tilqim) l antikorpi trażmessi lill-qżieqeż jistgħu jinterferixxu mal-immunizzazzjoni attiva fl-età ta' 12-il ġimgħa.
English: Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Maltese: TWISSIJIET SPEĊJALI Prekawzjonijiet speċjali li għandhom jittieħdu mill-persuna li tamministra l-prodott mediċinali veterinarju lill-annimali:
English: Pigs.
Maltese: Majjali.
English: Efficacy of the vaccine was examined in laboratory challenge studies in pigs without maternallyderived antibodies and was demonstrated against the following strains:
Maltese: L-effikaċja tat-tilqima ġiet eżaminata fi studji ta' sfida tal-laboratorju f'majjali mingħajr antikorpi derivati maternalment u ntweriet kontra r-razez li ġejjin:
English: Neutralising antibodies in serum have been detected in more than 75% of the immunised pigs on day 7 after primary immunisation lasting in more than 75% of the pigs for over 3 months.
Maltese: Antikorpi newtralizzanti fis-serum instabu f'aktar minn 75% tal-majjali mlaqqma fis-7 ġurnata wara immunizzazzjoni primarja li damet, f'aktar minn
English: Efficacy of the vaccine was examined in laboratory challenge studies in pigs without maternallyderived antibodies and was demonstrated against the following strains;
Maltese: L-effikaċja tat-tilqima ġiet eżaminata fi studji ta' sfida tal-laboratorju f'majjali mingħajr antikorpi derivati maternalment u ntweriet kontra r-razez li ġejjin;
English: 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Maltese: .6 Prekawzjonijiet speċjali għar-rimi tal-prodotti mediċinali veterinarji mhux użati jew materjal ieħor għar-rimi li huwa derivat minn dawn il-prodotti
English: Clear to slightly turbid, reddish to pale-pink coloured suspension.
Maltese: Żomm il-kunjett fil-pakkett ta' barra biex tipproteġi mid-dawl.
English: The full EPAR for Lantus can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: EPAR summary for the public insulin glargine
Maltese: Sommarju tal-EPAR għall-pubbliku insulin glargine
English: A total of 2,106 patients received Lantus in all trials combined.
Maltese: Total ta' 2,106 pazjenti rċevew Lantus fil-provi kollha kkombinati.
English: This summary was last updated in 05-2012.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'05-2012.
English: The active substance in Lantus, insulin glargine, is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin glargine.
Maltese: Is-sustanza attiva f'Lantus, insulina glargine, hija magħmula permezz ta' metodu magħruf bħala 'teknoloġija tad-DNA rikombinanti': hija magħmula minn batterju li rċieva ġene (DNA), li jagħmlu kapaċi jipproduċi insulina glargine.
English: This document is a summary of the European Public Assessment Report (EPAR) for Lantus.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Lantus.
English: Lantus is a solution for injection that contains the active substance insulin glargine.
Maltese: Lantus huwa soluzzjoni għal injezzjoni li fiha s-sustanza attiva insulina glargine.
English: Further studies have also been carried out to compare Lantus and human insulin NPH in patients with type 1 diabetes aged between five and 18 years, 200 of whom received Lantus, and in children aged two to six years, 61 of whom received Lantus.
Maltese: Saru aktar studji biex iqabblu Lantus u insulina tal-bniedem NPH f'pazjenti li għandhom id-dijabete tattip 1 ta' etajiet bejn ħamsa u 18-il sena, 200 minnhom irċevew Lantus, u fi tfal ta' etajiet ta' sentejn sa sitt snin, li 61 minnhom ħadu Lantus.
English: What is Lantus?
Maltese: X'inhu Lantus?
English: Why has Lantus been approved?
Maltese: Għaliex ġie approvat Lantus?
English: Insulin glargine is very slightly different from human insulin.
Maltese: L-insulina glargine hija ftit biss differenti mill-insulina tal-bniedem.
English: Reactions at the site of the injection (redness, pain, itching and swelling) and skin reactions (rash) have been seen more often in children than in adults.
Maltese: Reazzjonijiet fil-punt tal-injezzjoni (ħmura, uġigħ, ħakk u nefħa) u reazzjonijiet tal-ġilda (raxx) dehru aktar ta' spiss fit-tfal milli fl-adulti.
English: The main studies compared Lantus given once a day at bedtime with human insulin NPH (an intermediate-acting insulin) given once or twice a day.
Maltese: L-istudji ewlenin qabblu Lantus mogħti darba kuljum fil-ħin ta' qabel l-irqad ma' insulina umana NPH (insulina b'azzjoni intermedja) mogħti darba jew darbtejn kuljum.
English: It should be given in the evening in patients aged less than 18 years.
Maltese: F'pazjenti li għandhom inqas minn 18-il sena, għandu jingħata filgħaxija.
English: Lantus led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with human insulin.
Maltese: Lantus wassal għal tnaqqis fil-livell ta' HbA1c, u dan jindika li l-livelli tal-glukożju fid-demm kienu ġew ikkontrollati għal livell simili għal dak li jidher b'insulina umana.
English: What is the risk associated with Lantus?
Maltese: X'inhu r-riskju assoċjat ma' Lantus?
English: In adults (aged 18 years or over), it can be given at any time, provided that it is at the same time each day.
Maltese: Fl-adulti (minn 18-il sena 'il fuq), jista' jingħata fi kwalunkwe ħin bilkundizzjoni li dan isir dejjem fl-istess ħin tal-jum.
English: All of the studies measured the level of ‘fasting' blood glucose (measured when the patients had not eaten for at least eight hours) or a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
Maltese: L-istudji kollha kejlu l-livell ta' glukożju fid-demm 'fi stat ta' sawm' (imkejjel wara li ma jittiħidx ikel għal tal-inqas tmien sigħat) jew ta' sustanza fid-demm magħrufa bħala emoglobina glikosilata (HbA1c), li tagħti indikazzjoni fuq kemm ikun qiegħed jiġi kkontrollat tajjeb il-glukożju fid-demm.
English: Lantus is given by injection under the skin in the abdominal wall (tummy), the thigh, or the deltoid region (shoulder).
Maltese: Lantus jingħata permezz ta' injezzjoni taħt il-ġilda addominali (żaqq), il-koxxa, jew fir-reġjun deltojde (spalla).
English: How does Lantus work?
Maltese: Lantus jingħata darba kuljum.
English: It is available as vials, cartridges and prefilled disposable pens (OptiSet and SoloStar).
Maltese: Tiġi bħala kunjetti, skrataċ jew pinen mimlija minn qabel (OptiSet u SoloStar).
English: The most common side effect with Lantus (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels).
Maltese: L-iktar effett sekondarju komuni b'Lantus (li deher f'iktar minn pazjent 1 minn kull 10) hija ipogliċemija (livelli baxxi ta' glukożju fid-demm).
English: Lantus was originally studied in 10 studies, in both type 1 diabetes (when the pancreas cannot produce insulin) and type 2 diabetes (when the body is unable to use insulin effectively).
Maltese: Lantus kien oriġinarjament studjat f'10 studji, kemm f'dijabete tat-tip 1 (meta l-frixa ma tkunx tista' tipproduċi insulina) kif ukoll dijabete tat-tip 2 (meta l-ġisem ma jkunx kapaċi juża l-insulina b'mod effettiv).
English: Lantus can also be given together with antidiabetes medicines taken by mouth in patients who have type 2 diabetes.
Maltese: Lantus jista' jingħata wkoll flimkien ma' mediċini kontra d-dijabete mogħtijin mill-ħalq f'pazjenti li għandhom id-dijabete tat-tip 2.
English: Lantus is a replacement insulin that is very similar to the insulin made by the body.
Maltese: Lantus huwa insulina ta' sostituzzjoni simili ħafna ta' dik li jagħmel il-ġisem.
English: Lantus was effective in managing diabetes in adults and children aged two years and above.
Maltese: Lantus kien effettiv fil-kontroll taddijabete f'adulti u fi tfal ta' etajiet ta' sentejn u aktar.
English: Studies have also been carried out in nearly 1,400 adults with type 1 or type 2 diabetes to measure the effectiveness of Lantus injected at any time during the day, compared with an injection given in the evening.
Maltese: Saru wkoll studji fi kważi 1,400 adult b'dijabete tat-tip 1 u tat-tip 2 biex ikejlu l-effikaċja ta' Lantus injettat fi kwalunkwe ħin tal-jum, imqabbla ma' injezzjoni mogħtija filgħaxija.
English: The CHMP decided that Lantus's benefits are greater than its risks and recommended that it be given marketing authorisation.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Lantus huma akbar mir-riskji tiegħu u rrakkomanda li Lantus jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: How has Lantus been studied?
Maltese: Kif ġie studjat Lantus?
English: 27 80689 Munich Germany
Maltese: 80689 Munich
English: ATCvet code: QP53AG03
Maltese: QP53AG03
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <Date of first authorisation:> 01/02/2018
Maltese: <Data tal-ewwel awtorizzazzjoni:> 01/02/2018
English: It acts as contact poison against Varroa destructor.
Maltese: Dan jaġixxi bħala valenu ta' kuntatt kontra Varroa destructor.
English: <{MM/YYYY}> <{DD/MM/YYYY}> <{DD month YYYY}>
Maltese: M'hemm x bżonn ta' MRL
English: 4.6 Adverse reactions (frequency and seriousness)
Maltese: 4.6 Reazzjonijiet avversi (frekwenza u gravità)
English: 6.1 List of excipients
Maltese: 6.1 Lista ta' ingredjenti Soluzzjoni:
English: Citric acid monohydrate Glycerol (85%) Water, purified
Maltese: Monoidrat tal-aċidu ċitriku Gliċerol (85 %)
English: The active substance in Oxybee is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Maltese: Is-sustanza attiva f'Oxybee hija sustanza ammissibbli kif deskritt fit-tabella numru 1 fl-anness għarRegolament tal-Kummissjoni (UE) Nru 37/2010:
English: Preparation of the final bee-hive dispersion:
Maltese: Il-preparazzjoni tad-dispersjoni finali:
English: Wear personal protective equipment.
Maltese: Ilbes tagħmir ta' protezzjoni personali.
English: METHOD AND ROUTE(S) OF ADMINISTRATION In-hive use
Maltese: METODU U MOD(I) TA' AMMINISTRAZZJONI
English: Avoid oral exposure, including hand-to-mouth contact.
Maltese: Evita esponiment orali, inkluż kuntatt mill-idejn għal mal-ħalq.
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 colonies treated displaying adverse reaction(s)) - common (more than 1 but less than 10 colonies in 100 colonies treated) - uncommon (more than 1 but less than 10 colonies in 1,000 colonies treated) - rare (more than 1 but less than 10 colonies in 10,000 colonies treated) - very rare (less than 1 colony in 10,000 colonies treated, including isolated reports.
Maltese: - komuni (aktar minn waħda iżda inqas minn 10 kolonji f'100 kolonja kkurata) - mhux komuni (aktar minn waħda iżda inqas minn10 kolonji f'1,000 kolonja kkurata)
English: Dose:
Maltese: Doża:
English: White crystalline powder.
Maltese: Trab kristallin abjad.
English: A maximum dose of 5-6 ml of the final bee-hive dispersion should be administered once per seam occupied by bees.
Maltese: Doża massima ta' 5-6 ml tad-dispersjoni finali tad-doqqajs għandha tiġi amministrata darba għal kull ħajta okkupata min-naħal.
English: The dispersion should be warm (30 - 35 °C) during application.
Maltese: Id-dispersjoni għandha tkun sħuna (30 - 35 °C) meta tiġi applikata.
English: For the treatment of varroosis (Varroa destructor) of honey bees (Apis mellifera) in brood-free colonies.
Maltese: Għall-kura tal-varroażi (Varroa destructor) tal-għasel tan-naħal (Apis mellifera) f'kolonji mingħajr doqqajs.
English: 17.5 g oxalic acid dihydrate (equivalent to 12.5 g of oxalic acid) (375 g solution) 35 g oxalic acid dihydrate (equivalent to 25.0 g of oxalic acid) (750 g solution)
Maltese: 17.5 g ta' diidrat tal-aċidu ossaliku (ekwivalenti għal 12.5 g ta' aċidu ossaliku) (soluzzjoni ta' 375 g) 35 g ta' diidrat tal-aċidu ossaliku (ekwivalenti għal 25.0
English: insecticides
Maltese: FARMAĊEWTIKU
English: In-hive use.
Maltese: Mhux applikabbli.
English: Bees
Maltese: UŻU
English: Honey: Zero days.
Maltese: (honey supers).
English: TARGET SPECIES Honey bees (Apis mellifera)
Maltese: Naħal tal-għasel (Apis mellifera)
English: Four-layered foil (low-density polyethylene (LDPE)/ aluminium/ LDPE/ clay-coated paper) sealed sachets containing 125 g of flavoured sucrose.
Maltese: Qratas issiġillati b'fojl b'erba' saffi (polietilen b'densità baxxa (LDPE)/ aluminju/ LDPE/ karta miksija bit-tafal) li fihom 125 g ta' sukrożju bit-togħma.
English: For the full list of excipients, see section 6.1
Maltese: Għall-lista sħiħa ta' l-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
English: 125 g sucrose 250 g sucrose
Maltese: 125 g ta' sukrożju 250 g ta' sukrożju
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Maltese: Informazzjoni dettaljata dwar dan il-prodott mediċinali għall-użu veterinarju tinstab fuq il-websajt talAġenzija Ewropea dwar il-Mediċini (http://www.ema.europa.eu/).
English: Oxalic acid dihydrate 39.4 mg (equivalent to 28.1 mg of oxalic acid)
Maltese: 39.4 mg ta' diidrat tal-aċidu ossaliku (ekwivalenti għal 28.1 mg ta' aċidu ossaliku)
English: 375 g oxalic acid dihydrate solution to achieve 444 ml bee-hive dispersion.
Maltese: Soluzzjoni ta' 375 g ta' diidrat tal-aċidu ossaliku biex tinkiseb dispersjoni ta' 444 ml ta' doqqajs.
English: Pharmacotherapeutic group: Ectoparasiticides, insecticides and repellents; Ectoparasiticide for topical use, incl.
Maltese: Ektoparassitiċidi, insettiċidi u repellenti; Ektoparassitiċida għal użu topikali, inklużi insettiċidi
English: EU/2/17/216/002 (750 g g solution)
Maltese: EU/2/17/216/001 (soluzzjoni ta' 375 g) EU/2/17/216/002 (soluzzjoni ta' 750 g)
English: High-density polyethylene (HDPE) bottle with an HDPE/ polypropylene (PP) child-proof screw cap containing 375 g or 750 g solution.
Maltese: Flixkun tal-polietilen ta' densità għolja (HDPE) b'tapp b'kamin reżistenti għat-tfal talHDPE/prolipropelin (PP) li fih soluzzjoni ta' 375 g jew 750 g.
English: Preparation of the final dispersion:
Maltese: Dispersjoni finali tad-doqqajs (wara t-taħlit):
English: Preparation of the 888 ml final bee-hive dispersion: Pour the content of the two sachets into the bottle containing 750 g of the oxalic acid oxalic dihydrate acid solution.
Maltese: Il-preparazzjoni tad-dispersjoni finali ta' 888 ml: Itfa' l-kontenut taż-żewġ qratas fi flixkun li fih 750 g tas-soluzzjoni tad-diidrat tal-aċidu ossaliku.
English: Sucrose Anise oil Eucalyptus oil
Maltese: Dispożizz jonijiet oħrajn
English: MARKETING AUTHORISATION NUMBER(S) EU/2/17/216/001-002
Maltese: EU/2/17/216/001-002
English: Sachet:
Maltese: Flixkun:
English: Mix with Oxybee solution before use.
Maltese: Ħallat mas-soluzzjoni Oxybee qabel l-użu.
English: After mixing the bee-hive dispersion: Store in a refrigerator (2 °C - 8 °C).
Maltese: Aħżen fi friġġ (2°C - 8°C).
English: One cardboard box containing one 1000 ml bottle (containing 750 g oxalic acid dihydrate solution) and two sachets (each containing 125 g sucrose powder), providing 888 ml of the final bee-hive dispersion after mixing.
Maltese: Kaxxa tal-kartun waħda li fiha flixkun wieħed ta' 1000 ml (b'750 g ta' soluzzjoni ta' diidrat tal-aċidu ossaliku) u żewġ qratas (kull wieħed b'125 g ta' trab tas-sukrożju), li jipprovdu 888 ml tad-dispersjoni finali tad-doqqajs wara t-taħlit.
English: Therefore, if necessary, the dose per seam should be reduced in order not to exceed the maximum total amount administered per colony (calculation: maximum dose per colony/number of occupied seams= x.x ml/seam).
Maltese: Għalhekk, jekk meħtieġ, id-doża għal kull ħajta għandha titnaqqas sabiex ma jinqabiżx lammont totali massimu amministrat għal kull kolonja (kalkolu: doża massima għal kull kolonja/numru ta' ħjut okkupati= x.x ml/ħajta).
English: 4.11 Withdrawal period(s)
Maltese: 4.11 Perjod(i) ta' tiżmim
English: One cardboard box containing one 500 ml bottle (containing 375 g oxalic acid dihydrate solution) and one sachet (containing 125 g sucrose powder), providing 444 ml of the final bee-hive dispersion after mixing.
Maltese: Kaxxa tal-kartun waħda li fiha flixkun wieħed ta' 500 ml (li fih soluzzjoni ta' 375 g ta' diidrat tal aċidu ossaliku) u qartas wieħed (li fih 125 g ta' trab sukrożju), li jipprovdu 444 ml tad-dispersjoni finali tad-doqqajs wara t-taħlit.
English: Avoid disturbance to the hives the days after treatment.
Maltese: Evita li tiddisturba d-doqqajs fil-jiem wara l-kura.
English: Ask your veterinary surgeon how to dispose of medicines no longer required.
Maltese: Staqsi lill-kirurgu veterinarju tiegħek dwar kif l-aħjar li tarmi l-mediċini li ma jkunux meħtieġa aktar.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/17/216/001 (375 g g solution)
Maltese: EU/2/17/216/001 (soluzzjoni ta' 375 g g) EU/2/17/216/002 (soluzzjoni ta' 750 g g)